Sigil Biosciences | San Diego, CA
Building the data infrastructure
for virtual biology
The limiting factor
in AI for biology is no longer models or compute, but the lack of high-fidelity, scalable data.
We are bridging physical and virtual biology by extending high-throughput wet lab methods to access previously inaccessible biology and by enabling frontier AI models to learn from it.
The Platform
Sigil’s platform unifies physical and digital infrastructure into a vertically integrated, full-stack system
with multiple layers of innovation and intelligence across the stack.
Anchored in fully owned IP, this architecture positions us to define the next performance frontier
in drug discovery, precision medicine, and programmable biology.
STEP 1
Wet Lab Innovation
Novel physics-driven workflow
unlocks previously inaccessible biology
to existing high-throughput lab methods
STEP 2
Novel Biological Data
Novel data + known formats
ensure immediate compatibility
with the existing virtual biology ecosystems.
STEP 3
Virtual Biology Impact
Unlocks model learning through novel biological data.
Delivers proprietary data across the full stack.
Every layer is AI-enabled.
2022
Initial IP filed;
first manual prototype developed
2023
Sigil PCT conversions backed
by externally manufactured prototype data
2026
First US patent granted;
clean prosecution history
100%
Founder developed
and funded to date
Founding Team
Our Team
Our founding team has deep roots in life sciences, multiple ventures behind, and over ten years of innovating side by side.
Based in San Diego, CA
Raj Krishnan, PhD
Founder & CEORaj is scientist and engineer who creates the innovation that makes novel virtual biology possible.
Iryna Clark, MBA
Founder & COOIryna builds the conditions under which transformative technologies reach the world.
$102M
raised in prior ventures
53
issued patents in prior ventures
14
Peer reviewed publications
2
Sigil owned & developed patents
Advisory Team
Our multidisciplinary advisory board unites pioneering scientists from Stanford and UCSF, serial founders, and AI industry leaders, bringing deep expertise across biology, AI, and virtual biology with a proven track record of translating breakthrough science into category-defining companies.
-
Michael Snyder, PhD
Dr. Snyder is a pioneer in data-driven biology and precision medicine, Stanford professor and Director of the Center for Genomics and Personalized Medicine, with a track record of inventing foundational genomics technologies and generating large-scale multi-omic datasets. He has co-founded 17 companies (incl. 2 unicorns) with a combined enterprise value exceeding $6B.
-
Russ Altman, MD, PhD
Dr. Altman is a leader in AI-driven biology and medicine, Stanford professor, National Academy of Medicine member, and Associate Director of Stanford HAI, with a track record of building foundational biological data platforms and advancing data-driven approaches to drug discovery.
-
Michelle Arkin, PhD
Dr. Arkin is Vice Dean of Research Technology & Entrepreneurship at UCSF, Distinguished Professor of Pharmaceutical Chemistry, and Executive Director of the Small Molecule Discovery Center. A serial founder (Ambagon Therapeutics and Elgia Therapeutics) she has a track record of translating breakthrough science into therapeutic companies.
-
Trenton Norris
Trent is a healthcare AI executive and serial builder with deep experience scaling emerging technologies, having led GTM and partnerships at NVIDIA and Microsoft.
-
Dave S. B. Hoon, PhD
Dr. Hoon is a pioneer of circulating tumor DNA and liquid biopsy and a globally recognized leader in translational molecular oncology; Professor & Director of Translational Molecular Medicine, Saint John's Cancer Institute; 30+ patents, 475+ publications, 30+ NCI grants.